FDMT

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for severe cardiovascular and pulmonary diseases. The company's proprietary platform creates targeted and evolved adeno-associated virus (AAV) vectors designed for specific tissues and disease applications. 4D Molecular Therapeutics' lead programs address conditions including Fabry disease, cystic fibrosis, and pulmonary arterial hypertension. The company's Therapeutic Vector Evolution platform combines directed evolution with machine learning to optimize vector performance. Clinical trials are evaluating the safety and efficacy of these novel gene therapy candidates.